GID Group

About GID Group

The GID Group specializes in developing innovative cellular therapies aimed at treating knee osteoarthritis. Operating within the healthcare sector, the company primarily serves healthcare providers and patients seeking advanced treatment options for pain and functional impairments associated with osteoarthritis. The GID Group's business model revolves around leveraging adipose tissue processing to create stromal vascular fraction (SVF) cells, which are used in their proprietary treatments. These treatments are designed to offer regenerative capabilities that traditional blood cells lack. The company generates revenue through the sale of its cellular therapy products and services to healthcare providers, who then administer these treatments to patients. The GID Group's market includes both domestic and international healthcare providers, with a focus on expanding its global footprint. The company's leadership team comprises experienced professionals with extensive backgrounds in healthcare, sales, and biotechnology, ensuring a robust strategy for growth and innovation.